Table 2 Prevalence (%) of comorbid conditions at baseline in the study population (n = 261), grouped according to comorbidity index and serum adiponectin (mcg/ml) levels.

From: Comorbidity burden may explain adiponectin’s paradox as a marker of increased mortality risk in hemodialysis patients

Comorbid conditionsa

CI ≤ 4 (n = 142)

CI > 4 (n = 119)

MANOVAc

Low Adb

(n = 78)

High Ad

(n = 64)

Low Ad

(n = 52)

High Ad

(n = 67)

Ischemic heart disease

23.1

23.8

55.8

59.7

CI

Congestive heart failure

5.1

4.8

59.6

70.1

CI

Cerebrovascular disease

6.4

6.3

30.8

43.3

CI

Peripheral vascular disease

2.6

3.2

21.2

35.8

CI, Ad

Dysrhythmia

10.3

14.3

40.4

34.3

CI

Other cardiac disease

1.3

4.8

11.5

23.9

CI, Ad

Lung disease

2.6

11.1

32.7

26.9

CI

Gastrointestinal bleeding

3.8

0.0

9.6

7.5

CI

Liver disease

9.0

4.8

15.4

6.0

NS

Cancer

14.1

19.0

28.8

22.4

NS

Diabetes mellitus

47.4

50.8

71.2

71.6

CI

  1. CI, comorbidity index; NS, non-significant; Ad, adiponectin.
  2. aSee Methods for definitions of comorbid conditions.
  3. bLow adiponectin was defined as adiponectin < 8.28mcg/ml, the valuebelow the medianof distribution.
  4. cTwo-factor MANOVA. Significant (p < 0.05) effects are given for comorbidity index (CI), adiponectin (Ad), and the interaction of comorbidity index with adiponectin (CI × Ad).
Back to article page